Skip to Content

Join the 'Renal Cell Carcinoma' group to help and get support from people like you.

Renal Cell Carcinoma News

Related terms: Adenocarcinoma of renal cells, Cancer, Hypernephroma, Cancer, Kidney, Cancer, Renal, Cancer, Renal Cell Carcinoma, Hypernephroma, Kidney Cancer, Renal Cancer

'Heat Zapping' Kidney Tumors May Help Some Patients Avoid Surgery

Posted 26 Jun 2018 by Drugs.com

TUESDAY, June 26, 2018 – When kidney cancer strikes, surgical removal of the organ is often the standard course of action. But new research supports a nonsurgical approach for some patients: using a needle to "zap" kidney tumors away with either heat or cold. The procedure – known as percutaneous ablation – isn't applicable to all kidney cancer patients. But for a "well-selected" group with ...

Sunitinib (Sutent) May Spare Some Kidney Cancer Patients From Organ Removal

Posted 4 Jun 2018 by Drugs.com

MONDAY, June 4, 2018 – Many people with advanced kidney cancer might not need to have their kidneys removed during treatment, something that until now has been standard practice. Patients who only received a targeted drug for their kidney cancer survived just as well as those who had their cancerous organ removed before drug therapy, according to a new clinical trial. "We believe this one study ...

FDA Approves Opdivo (nivolumab) + Yervoy (ipilimumab) Combination as First-Line Treatment for Patients with Intermediate- and Poor-Risk Advanced Renal Cell Carcinoma

Posted 7 May 2018 by Drugs.com

PRINCETON, N.J.--(BUSINESS WIRE) April 16, 2018 --Bristol-Myers Squibb Company (NYSE: BMY) today announced that Opdivo (nivolumab) 3 mg/kg plus Yervoy (ipilimumab) 1 mg/kg (injections for intravenous use) was approved by the U.S. Food and Drug Administration (FDA) as the first Immuno-Oncology combination therapy for previously untreated patients with intermediate- and poor-risk advanced renal ...

Belly Fat Tied to Lower Kidney Cancer Survival Odds in Women

Posted 9 Apr 2018 by Drugs.com

MONDAY, April 9, 2018 – Belly fat reduces a woman's chances for surviving kidney cancer, but not a man's, a new study suggests. The study included 77 women and 145 men with kidney cancer. Half of the women with high amounts of belly fat died within 3.5 years of diagnosis. Meanwhile, more than half of women with low amounts of belly fat were still alive after 10 years. Researchers at Washington ...

Bristol-Myers Squibb’s Opdivo (nivolumab) Now the First and Only FDA-Approved PD-1 Inhibitor to Offer Every Four-Week Dosing

Posted 14 Mar 2018 by Drugs.com

PRINCETON, N.J.--(BUSINESS WIRE) March 6, 2018 --Bristol-Myers Squibb Company (NYSE:BMY) today announced the U.S. Food and Drug Administration (FDA) has approved a supplemental Biologics License Application (sBLA) updating the Opdivo (nivolumab) dosing schedule to include 480 mg infused every four weeks (Q4W) for a majority of approved indications.1 This approval will provide health care ...

Exelixis Announces U.S. FDA Approval of Cabometyx (cabozantinib) Tablets for Previously Untreated Advanced Renal Cell Carcinoma

Posted 16 Jan 2018 by Drugs.com

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Dec. 19, 2017-- Exelixis, Inc. (NASDAQ:EXEL) today announced that the U.S. Food and Drug Administration (FDA) approved Cabometyx (cabozantinib) tablets for the expanded indication of patients with advanced renal cell carcinoma (RCC). RCC is the most common form of kidney cancer in adults. The FDA’s priority review and approval of Cabometyx was based o ...

FDA Approves Sutent (sunitinib malate) for Adjuvant Treatment of Adult Patients at High Risk of Recurrent Renal Cell Carcinoma

Posted 20 Nov 2017 by Drugs.com

November 16, 2017 – The U.S. Food and Drug Administration today approved Sutent (sunitinib malate) for the adjuvant treatment of adult patients who are at a high risk of kidney cancer (renal cell carcinoma) returning after a kidney has been removed (nephrectomy). Adjuvant treatment is a form of therapy that is taken after an initial surgical removal to lower the risk of the cancer coming back. ...

FDA Approves Mvasi (bevacizumab-awwb), a Biosimilar to Avastin

Posted 17 Sep 2017 by Drugs.com

September 14, 2017 – The U.S. Food and Drug Administration today approved Mvasi (bevacizumab-awwb) as a biosimilar to Avastin (bevacizumab) for the treatment of multiple types of cancer. Mvasi is the first biosimilar approved in the U.S. for the treatment of cancer. “Bringing new biosimilars to patients, especially for diseases where the cost of existing treatments can be high, is an important w ...

FDA OKs First 'Biosimilar' Drug to Fight Cancer, Mvasi

Posted 14 Sep 2017 by Drugs.com

THURSDAY, Sept. 14, 2017 – The first approval of a biosimilar drug to treat cancer was announced Thursday by the U.S. Food and Drug Administration. Mvasi (bevacizumab-awwb) was approved as a biosimilar to Avastin (bevacizumab) for the treatment of adults with certain colon, lung, brain, kidney and cervical cancers. A biosimilar is a biological product that is approved because it is highly ...

Many Terminal Cancer Patients Remain in Denial

Posted 20 Jul 2017 by Drugs.com

WEDNESDAY, July 19, 2017 – Nearly 10 percent of patients with terminal cancer don't want to know they're dying, which can make their final days more difficult, a new study finds. Unwillingness to face poor prospects can lead to unnecessary treatments and keep patients from making end-of-life plans, the researchers reported recently in The Oncologist. "Health care professionals should ...

'Couch Potatoes' May Face Higher Risk of Kidney, Bladder Cancers

Posted 15 Jun 2017 by Drugs.com

THURSDAY, June 15, 2017 – Add greater risk of kidney and bladder cancer to the long list of why a lifetime of sitting on the sofa isn't good for your health, a new study suggests. Specifically, lifetime recreational inactivity was associated with a 73 percent increased risk of bladder cancer and a 77 percent increased risk of kidney cancer. The findings add to growing evidence that inactivity ...

Survival Continues to Improve for Most Cancers

Posted 31 Mar 2017 by Drugs.com

FRIDAY, March 31, 2017 – Overall cancer death rates in the United States continue to fall, but racial gaps persist, a new report says. Death rates fell between 2010 and 2014 for 11 of the 16 most common cancers in men and for 13 of the most common types in women, including lung, colon, prostate and breast cancers. However, death rates rose for cancers of the liver, pancreas and brain in men and ...

Another Study Ties Obesity to Certain Cancers

Posted 1 Mar 2017 by Drugs.com

WEDNESDAY, March 1, 2017 – Carrying extra weight increases the risk of a number of cancers, a new review reports. Additional pounds appear to particularly influence the risk of cancers related to the digestive organs or those driven by hormonal abnormalities, according to the review's European authors. The evidence is so strong at this point that important organizations such as the International ...

Toxins in Your Fast-Food Packaging?

Posted 1 Feb 2017 by Drugs.com

WEDNESDAY, Feb. 1, 2017 – Many grease-resistant fast-food wrappers and boxes contain potentially harmful chemicals that can leach into food, a new study contends. Testing on more than 400 samples from restaurants nationwide revealed that nearly half of fast-food wrappers and one out of five paperboard food boxes contained detectable levels of fluorine, said lead researcher Laurel Schaider. She's ...

Kidney Cancer Drug Shows Promise in Early Trial

Posted 30 Nov 2016 by Drugs.com

WEDNESDAY, Nov. 30, 2016 – An experimental drug may show promise in treating kidney cancer, researchers say. The drug CB-839 is the first to target an enzyme that cancer cells require to stay alive, researchers said. This stage 1 clinical trial found that the drug was effective in most patients with advanced kidney cancer when used in combination with another cancer drug called everolimus ...

Page 1 2 3 Next

Ask a Question

Further Information

Related Condition Support Groups

Wilms' Tumor, Cancer

Related Drug Support Groups

medroxyprogesterone, Votrient, Afinitor, Sutent, Avastin, Opdivo, Nexavar, capecitabine, nivolumab, view more... bevacizumab, erlotinib, Cabometyx, Mvasi, cabozantinib, everolimus, sorafenib, axitinib, lenvatinib, Proleukin, pazopanib, temsirolimus, Torisel, sunitinib, Inlyta, peginterferon alfa-2b, Lenvima, interferon alfa-2a, aldesleukin